Superworth

Evolus EPS EOLS

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$0.52
Latest quarter, Q2 FY26
−$0.12
Fiscal year 2025
−$0.81

Evolus' earnings per share was −$0.52 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.12.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.81n/a
FY2024−$0.81n/a
FY2023−$1.09n/a
FY2022−$1.32n/a
FY2021−$0.83n/a
FY2020−$4.84n/a
FY2019−$3.22n/a
FY2018−$1.93n/a
FY2017−$0.27n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.12n/a−$0.52
Q1 FY26−$0.16n/a−$0.67
Q4 FY25$0.00n/a−$0.81
Q3 FY25−$0.24n/a−$0.92
Q2 FY25−$0.27n/a−$0.98
Q1 FY25−$0.30n/a−$0.89
Q4 FY24−$0.11n/a−$0.81
Q3 FY24−$0.30n/a−$0.91
Q2 FY24−$0.18n/a−$0.91
Q1 FY24−$0.22n/a−$1.05
Q4 FY23−$0.21n/a−$1.09
Q3 FY23−$0.30n/a−$1.11

Against its peers

Companies in Drug Manufacturers - General nearest Evolus' size, closest first, today.

CompanyEPS, 12 monthsGrowth
EOLSEvolus−$0.52
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
NATRNatures Sunshine Products$1.01+36% a year
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
Peer median$0.97

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Evolus

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.